Form D · Biotechnology
Travus Therapeutics, Inc.
Winston Salem, NC · CIK 0001678007
Offering snapshot reported Jul 12, 2016 · SEC filing
- Reported sold
- $750K Offering amount: $2.25M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 6, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 12, 2016 | Initial | $750,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-266753
Securities offered consist of promissory notes convertible into shares of convertible preferred stock, warrants exercisable for shares of convertible preferred stock and the common stock underlying the convertible preferred stock.
Source: Form D, filed Jul 12, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jerel Davis | Director |
| John Finn | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
101 N. Chestnut St., Suite 104
Winston Salem, NC, 27101
Winston Salem, NC, 27101